MPM Oncology Impact Management »

Disc Medicine shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Disc Medicine (IRON) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Disc Medicine

Tip: Access up to 7 years of quarterly data

All positions including Disc Medicine held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Disc Medicine by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $14M 306k 45.07
2024-03-31 $6.9M 111k 62.26

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Disc Medicine

Paradigm Biocapital Advisors
Atlas Venture Life Science Advisors
Bain Capital Life Sciences Investors
OrbiMed Advisors
Frazier Life Sciences Management
BlackRock
T. Rowe Price Associates
Vanguard Group
Deerfield Management Company
Logos Global Management
Point72 Asset Management
Wellington Management Company
State Street Corporation
Adage Capital Partners GP
Perceptive Advisors

View all funds holding Disc Medicine